SCHEMBL5218142

SCHEMBL5218142

Cc1cc(-n2cc(-c3ccncn3)cn2)ccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.42
CYP19A1 P11511 1/20 0.41
JAK2 O60674 1/20 0.41
MKNK1 Q9BUB5 5/20 0.41
GRM4 Q14833 1/20 0.40
KCNH2 Q12809 7/20 0.40
GRM5 P41594 1/20 0.39
DCLK1 O15075 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
EGFR P00533 1/20 0.38
PRKACA P17612 1/20 0.38
FLT3 P36888 1/20 0.38
FRK P42685 1/20 0.38
MAPK9 P45984 1/20 0.38
CSNK1A1 P48729 1/20 0.38
GSK3B P49841 1/20 0.38
MINK1 Q8N4C8 1/20 0.38
SLK Q9H2G2 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14380712 0.88 PDE10A (0.44) PDE10AJAK2MKNK1GRM4GRM5
SCHEMBL8354842 0.85 PDE10A (0.42) PDE10AJAK2MKNK1GRM4GRM5
SCHEMBL5215357 0.85 PDE10A (0.47) PDE10AJAK2MKNK1GRM4GRM5
SCHEMBL5218730 0.82 PDE10A (0.47) PDE10AJAK2MKNK1GRM4GRM5
SCHEMBL12203764 0.81 PDE10A (0.46) PDE10AMKNK1GRM4GRM5FLT3
SCHEMBL5218758 0.80 PDE10A (0.46) PDE10AJAK2MKNK1GRM4GRM5
SCHEMBL5216629 0.78 PDE10A (0.44) PDE10AMKNK1GRM4GRM5MELK
SCHEMBL5216814 0.77 GRM5 (0.45) PDE10AMKNK1GRM4GRM5MAPK9
SCHEMBL28245414 0.77 PDE10A (0.46) PDE10AMKNK1GRM4KCNH2GRM5
SCHEMBL5219022 0.77 NPC1 (0.49) JAK2GRM4GRM5FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C PDE10A 964/4885CYP19A1 4160/4885JAK2 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.